Core Viewpoint - The research highlights the critical role of the three-dimensional spatial conformation of ionizable lipids in the effective delivery of mRNA, showcasing the potential of AI-driven strategies in optimizing organ-specific targeting of lipid nanoparticles (LNPs) for mRNA therapeutics [4][18]. Group 1: Research Findings - An AI model was developed to analyze the three-dimensional spatial conformation of ionizable lipids, leading to the identification of lipid P1, which exhibits a stable three-tailed conical structure that enhances mRNA delivery targeting the spleen [4][6]. - The mRNA vaccine delivered via P1-based LNPs triggered strong antibody and T cell responses in mouse tumor models, significantly inhibiting tumor growth [4][16]. - The study emphasizes that the spatial conformation of lipids is crucial for organ targeting, with the conical structure of P1 facilitating efficient mRNA loading, endosomal escape, and the formation of a protein corona that directs LNPs to immune cells in the spleen [11][12][18]. Group 2: Mechanism and Implications - The research transitioned the design of ionizable lipids from a trial-and-error approach to a rational design based on three-dimensional spatial conformation, inducing strong immune responses and achieving significant tumor suppression in melanoma and colon cancer models [18][19]. - The AI framework developed in this study can be applied to the design of delivery systems for other nucleic acid drugs, such as siRNA and DNA vaccines, paving the way for personalized medicine tailored to specific patient needs [19].

Core Viewpoint - The recent advancements in mRNA vaccines and genome editing therapies rely on the development and engineering of lipid nanoparticles (LNPs), which are non-viral delivery systems that effectively protect nucleic acids and deliver them to cells [3][4]. Group 1: Development of Targeted Delivery Systems - The research team led by Professor Daniel Siegwart developed organ-specific targeting LNPs, known as SORT-LNP, which enable mRNA delivery to organs outside the liver, such as the lungs and kidneys [3]. - A new study published in Nature Biomedical Engineering introduced tripod-like lung-targeting (LuT) lipids for constructing novel LNPs, achieving highly efficient and selective gene delivery and editing to the lungs [4]. Group 2: Design and Evaluation of LuT Lipids - The study systematically described the design, chemical synthesis, and biomedical evaluation of two lipid libraries, resulting in the synthesis of 444 quaternary ammonium lipids [7]. - The optimal LuT lipid features a unique "tripod-like" structure, consisting of a quaternary ammonium head as the core, three long alkyl chains as "legs," and a short chain as a "handle" [7]. - The screening process yielded a high success rate, with 39% of candidates from the first library and 67% from the second library demonstrating excellent performance [7]. Group 3: Performance and Implications of LuT LNPs - The best-performing LuT LNP, named 1A7B13 LNP, showed a 25.5-fold increase in mRNA delivery efficiency compared to the benchmark DOTAP SORT LNP and a 9.2-fold increase in gene editing efficiency using CRISPR–Cas9, with over 90% selectivity for lung delivery [9]. - The delivery of IL-10 mRNA via 1A7B13 LNP demonstrated promising therapeutic effects for acute lung injury, highlighting the relationship between lipid structure and lung-targeting activity [9].

Core Insights - The article discusses the significant role of lipid nanoparticles (LNP) in the delivery of therapeutic mRNA and highlights a recent study that enhances the efficiency of this delivery method through amino acid supplementation [2][3][6]. Group 1: Study Findings - The research published in Science Translational Medicine demonstrates that an amino acid supplement composed of methionine (Met), arginine (Arg), and serine (Ser) can significantly improve the in vivo delivery efficiency of LNP-mediated mRNA and gene editing [3][6]. - The study shows that the combination of LNP and the amino acid supplement can increase mRNA expression levels by 5 to 20 times in various cell types and lipid formulations [10]. - In preclinical mouse models, the co-administration of LNP and the amino acid supplement can enhance mRNA expression levels by 8 to 13 times through different administration routes [10]. Group 2: Mechanism of Action - The research indicates that the delivery efficiency of LNP is influenced by cellular metabolism, with physiological metabolic conditions limiting mRNA expression [7][10]. - The amino acid supplement enhances the clathrin-independent carrier (CLIC) pathway of cellular endocytosis, leading to improved uptake of LNP and the mRNA it carries [10]. - In acute liver injury mouse models, the combination of LNP delivering growth hormone mRNA and the amino acid supplement significantly improves liver growth hormone expression and reduces inflammation [10]. Group 3: Implications for Future Research - The findings suggest that transient modulation of the metabolic environment could be a novel strategy to enhance the effectiveness of LNP-based mRNA therapies and gene editing [6][10]. - The study emphasizes the importance of specific amino acid mixtures as co-delivery agents in improving the outcomes of mRNA-based cellular and gene therapies [10].

Core Viewpoint - The recent research by Chen Xiaoyuan and colleagues introduces a novel strategy called Metal-ion-assisted RNA folding (MARF) that significantly enhances mRNA delivery and protein production efficiency, addressing limitations in mRNA applications beyond infectious diseases [4][6][9]. Group 1: Research Background - Chen Xiaoyuan, previously affiliated with the National University of Singapore, has transitioned to Shandong First Medical University following allegations of misconduct [3]. - The new paper published in Nature Nanotechnology discusses the development of the MARF strategy, which utilizes specific metal ions to improve mRNA folding and delivery [4]. Group 2: Technical Details - The MARF strategy involves the use of metal ions (Mn²⁺, Mg²⁺, and Zn²⁺) to facilitate the folding of mRNA into more compact structures when delivered with lipid nanoparticles (LNP) [6]. - By adjusting the stoichiometry of mRNA and metal ions, the research demonstrates that the half-life of mRNA can be extended by up to 9 times, and protein expression levels can increase by 7.3 times [6]. Group 3: Implications and Applications - The enhanced interaction between mRNA-LNP and surrounding biological systems leads to improved intracellular processing and prolonged retention of mRNA in target cells [7]. - The MARF-LNP strategy has shown to significantly improve gene editing efficiency and durability for clinically relevant genes, such as PCSK9, with a single intravenous administration [7]. Group 4: Conclusion - This research highlights the potential of mechanical signals in the design of nanoparticles aimed at improving mRNA delivery, paving the way for more effective mRNA therapies [9].

Core Viewpoint - The study identifies a critical imbalance of NTRK2 isoforms in endothelial cells as a key driver of endothelial dysfunction in Bronchopulmonary Dysplasia (BPD), suggesting that mRNA therapy targeting NTRK2-FL could promote vascular regeneration and repair in affected lungs [3][5][7]. Group 1: Research Findings - The research reveals that the functional imbalance of NTRK2 isoforms in endothelial cells determines the regeneration outcomes of pulmonary microvessels after injury [3]. - A multi-omics analysis of endothelial cells isolated from human BPD lung tissue identified a common capillary endothelial cell (gCap) that is regulated by two different isoforms of NTRK2, with NTRK2-FL promoting repair and NTRK2-T1 leading to maladaptive responses [4][9]. - The use of lipid nanoparticle (LNP) delivered NTRK2-FL mRNA significantly restored capillary density and improved alveolar structure in a mouse model of hyperoxia-induced lung injury [4][9]. Group 2: Implications of the Study - The findings indicate that the isoform imbalance of NTRK2 is a critical factor in endothelial dysfunction, supporting the potential of isoform-specific RNA therapy as a promising strategy for vascular regeneration and repair [5][7]. - The research successfully demonstrates a method to revert the "bad switch" from NTRK2-FL to NTRK2-T1 back to a "good" state by restoring NTRK2-FL expression, thereby repairing damaged lung vasculature and alveolar structures [7].

Core Viewpoint - The research published by the University of Pennsylvania reveals that the strong immune response triggered by mRNA vaccines is a result of the synergistic interaction between two core components: modified mRNA and lipid nanoparticles (LNP), which together guide the immune system to produce effective germinal center responses, leading to the generation of durable neutralizing antibodies and memory B cells [1][2][18]. Group 1: Mechanism of mRNA Vaccines - mRNA vaccines deliver mRNA encoding viral proteins to human cells, prompting them to produce viral antigens and train the immune system. Early studies indicated that unmodified mRNA could cause excessive inflammatory responses, which scientists mitigated through nucleotide modifications [5][6]. - The study challenges the traditional view that modified mRNA is "immune-silent," demonstrating that mRNA components can induce the production of type I interferons (IFN-α and IFN-β), which activate dendritic cells (DC) and enhance the differentiation of follicular helper T (Tfh) cells, crucial for germinal center responses [8][9]. Group 2: Role of Lipid Nanoparticles (LNP) - LNPs, typically seen as mere carriers for mRNA, possess significant adjuvant activity, directly regulating the transcriptional program of dendritic cells and promoting Tfh cell differentiation [10][11]. - LNPs induce dendritic cells to express soluble CD25, which neutralizes IL-2, a cytokine that inhibits Tfh cell differentiation, thereby facilitating Tfh cell development [11]. - The study shows that LNPs enhance immune signaling locally at the injection site, explaining their high efficiency and safety [11][12]. Group 3: Synergistic Effects of mRNA and LNP - The research indicates that both mRNA and LNP components are essential for optimal immune responses. Using LNP alone with recombinant proteins resulted in weaker immune reactions compared to the combination with modified mRNA [13][14]. - The presence of mRNA enhances the quality of Tfh cells, making them more likely to produce IFN-γ and IL-21, which are critical for B cell responses, ultimately leading to stronger neutralizing antibody titers [13][14]. Group 4: Implications for Future Vaccine Design - This study not only elucidates the mechanisms behind the success of mRNA vaccines but also provides a blueprint for the design of next-generation vaccines. Adjustments to mRNA modifications or LNP components could precisely regulate the type and intensity of immune responses [16][18]. - The principles derived from this research could extend to cancer vaccines or infectious disease vaccines, enabling more effective immunotherapies [16].

Core Insights - Immune therapy has fundamentally changed the clinical approach to tumor treatment, particularly with PD-1/PD-L1 immune checkpoint inhibitors, which have received continuous FDA approvals for both monotherapy and combination therapy. However, the clinical benefits in advanced tumor patients remain limited due to low somatic mutation rates, few infiltrating lymphocytes, and low PD-L1 expression levels, indicating these tumors are "cold tumors" [2] - Various immune cytokines such as IL-2, IL-7, IL-12, and IL-15 have been identified to regulate T cell proliferation, survival, and function, with the potential to convert "cold tumors" into "hot tumors" and enhance anti-tumor responses when used in conjunction with immune checkpoint inhibitors. Nonetheless, their clinical application faces challenges including technical difficulties, safety concerns, and insufficient efficacy observed in advanced tumors [2] Group 1 - The recent study published in Cell Reports Medicine demonstrates the local delivery of IL-15 and anti-PD-L1 nanobody via in vitro transcribed circILNb, which activates robust anti-tumor immunity in "cold tumors" that are unresponsive to conventional immunotherapy [3][4] - The research team engineered a circCV-B3 vector to achieve scarless circular RNA (circRNA) engineering, allowing circILNb to co-encode IL-15 and anti-PD-L1 nanobody. This circILNb is purified through a biotin-avidin purification system and encapsulated in lipid nanoparticles (LNP) for intratumoral injection, leading to in situ protein expression and activation of existing CD8+ T cells and NK cells for local tumor control [6][8] Group 2 - The study highlights the potential of the circCV-B3 vector and BAPS as circRNA engineering methods, confirming that circILNb can serve as a non-protein therapeutic strategy for tumor immunotherapy [8]

Group 1 - The core viewpoint of the news is the collaboration between Baiaosaitu and Merck to evaluate antibody-conjugated lipid nanoparticles (Ab-LNP) for new applications in nucleic acid drug delivery, highlighting the strong interest in "precise delivery" in the biopharmaceutical sector [1][5] - The nucleic acid drug market is rapidly growing, with mRNA therapies gaining mainstream acceptance, but the delivery of nucleic acids remains a significant bottleneck [2][5] - The global lipid nanoparticle (LNP) market is projected to grow from $1.1 billion in 2025 to $3.5 billion by 2034, with a compound annual growth rate (CAGR) of 13.3% [2] Group 2 - Antibody-modified LNPs have shown promising results in animal models, significantly improving delivery efficiency to non-liver tissues, which is crucial for treating various diseases [2][3] - The partnership between Baiaosaitu and Merck marks the third deepening of their collaboration, indicating a new phase in the "antibody × delivery" model [4] - The trend towards platform and modular design in LNP technology is emerging, with new molecular forms like antibodies and bispecific antibodies expanding delivery capabilities [4] Group 3 - The investment landscape is shifting towards antibody-conjugated LNPs as a potential solution to the delivery bottleneck in nucleic acid drugs, with significant capital being directed into this area [3][5] - The collaboration between Baiaosaitu and Merck reflects the increasing involvement of Chinese biotech companies in the global restructuring of drug delivery technologies [5]

Core Viewpoint - The article discusses the development of a peptide-encoded organ-selective targeting (POST) method that enhances the delivery of mRNA to extrahepatic organs using lipid nanoparticles (LNP) [4][11]. Group 1: mRNA Delivery and LNP Technology - mRNA-based gene and protein replacement technologies present significant opportunities for vaccine, cancer treatment, and regenerative therapy development [2]. - LNPs have been widely adopted as delivery vehicles for mRNA COVID-19 vaccines, demonstrating their safety and efficacy [2]. - Achieving organ-selective delivery of LNPs containing mRNA remains challenging, particularly for extrahepatic organs [2][4]. Group 2: Advances in Organ-Selective Delivery - Recent studies have made progress in organ-selective delivery through simple binary charge modulation and lipid chemical modifications, but these strategies are limited by the rational design of the LNP-environment interface [2][4]. - The POST method utilizes specific amino acid sequences to engineer the surface of LNPs, allowing for efficient mRNA delivery to extrahepatic organs after systemic administration [4][7]. Group 3: Mechanism and Applications - The targeting mechanism of the POST system is based on the optimization of the mechanical affinity between peptide sequences and plasma proteins, forming a specific protein corona around the LNPs [4][9]. - The POST code does not rely on the charge of LNPs for organ selectivity, but rather on the unique protein corona formed, which is influenced by the amino acid sequence [9]. - The POST code is applicable to various LNP formulations and can facilitate the selective delivery of mRNA to organs such as the placenta, bone marrow, adipose tissue, and testes [9][11]. Group 4: AI and Computational Design - The research team developed an AI-based framework using a Transformer-based protein language model to generate peptide sequences with high mechanical affinity for specific proteins, demonstrating the potential of computational design in guiding LNP organ targeting [9][11]. - The peptide sequence RRRYRR was shown to enable selective delivery of mRNA to the lungs, supporting the feasibility of using computer-aided rational design for POST-LNP organ-selective delivery [9][11].

Core Viewpoint - The development of mRNA and lipid nanoparticles (LNP) has shown significant clinical success in delivering gene drugs to the liver, but the tendency of LNP to accumulate in the liver poses a major bottleneck for broader applications in gene therapy [2][4]. Group 1: Research Development - A collaborative research paper titled "Tissue-specific mRNA delivery and prime editing with peptide–ionizable lipid nanoparticles" was published in Nature Materials, showcasing a new platform for organ-targeted mRNA delivery [3]. - The research combines peptides and ionizable lipids to create a novel material called peptide-ionizable lipid (PIL), establishing a platform (PILOT) for organ-specific and tunable mRNA delivery [4][5]. Group 2: Engineering and Design - Researchers have invested significant effort into engineering mRNA-LNP to reach organs beyond the liver, utilizing ligand coupling, component optimization, and the development of new ionizable lipids [7]. - The study highlights the importance of ionizable lipids in determining the efficacy and organ selectivity of LNP, with a focus on customizing lipid structures through combinatorial chemistry [7][8]. Group 3: Synthesis and Modifications - The research team developed over 120 structurally diverse PILs using solid-phase supported synthesis (SPSS), which offers advantages over traditional liquid-phase synthesis [9]. - Specific modifications to amino acids, such as lysine and arginine, enhance mRNA delivery to the lungs, while cysteine and histidine modifications target the liver [11]. Group 4: Efficacy and Safety - The PILOT platform demonstrated effective delivery of Cre mRNA, achieving specific gene editing in targeted tissues, with editing efficiencies of 13.1% in the liver and 7.4% in the lungs [13]. - The study provides a universal design strategy for developing organ-targeted ionizable lipids, indicating the potential of the PILOT LNP platform in advancing organ-specific gene editing therapies [15].